Trailing-twelve-month (TTM) revenue is $8.22 Million with a year-over-year growth of (51.05%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $3,299,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-06 |
| Q4 FY2025Period ended 2025-12-31 | $1,295,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $1,996,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $1,629,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $8,219,000 |
Current P/S: $516,755,616 market capitalization ÷ $8,219,000 TTM revenue = 62.87x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:01.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $1.63M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T20:10:21.390Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Contract research | N/A | $6M | $4M | $3M | $3M | $2M |
| License and Service | N/A | N/A | $25M |
$8.22M
$8.22 Million
(51.05%)
vs. $16.79M a year ago (TTM)
+4.39%
5 Year compound annual growth rate
1 Year
(51.05%)
3 Year
(35.87%)
5 Year
+4.39%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $7.83M | ($10.89M) | (58.19%) |
| 2024 | $18.72M | ($12.53M) | (40.09%) |
| 2023 | $31.25M | +$1.50M | +5.03% |
| 2022 | $29.75M | +$22.99M | +340.05% |
| 2021 | $6.76M | +$279,000 | +4.30% |
| 2020 |
TTM Growth
(51.05%)
3-Year CAGR
(35.87%)
5-Year CAGR
+4.39%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 32 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T20:10:21.390Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| $28M |
| $16M |
| $6M |
| Other | N/A | N/A | $257,000 | N/A | N/A | N/A |
|---|
| Other revenue | N/A | $931,000 | N/A | N/A | N/A | N/A |
|---|
| Product | $424,000 | N/A | N/A | N/A | N/A | N/A |
|---|
| Rhofade Product | $424,000 | N/A | N/A | N/A | N/A | N/A |
|---|
| $6.48M |
| +$2.25M |
| +53.35% |
| 2019 | $4.23M | ($5.86M) | (58.11%) |
| 2018 | $10.09M | +$8.41M | +499.58% |
